Literature DB >> 18294941

The role of Doppler Perfusion Index as screening test in the characterization of focal liver lesions.

K Kyriakopoulou1, A Antoniou, I V Fezoulidis, N L Kelekis, G N Dalekos, M Vlychou.   

Abstract

PURPOSE: Doppler Perfusion Index (DPI) has been used in the detection of overt liver metastatic disease. In the present prospective study we evaluated the use of DPI in the differential diagnosis of liver tumours.
MATERIALS AND METHODS: We have included in our study 76 patients with focal hepatic lesion and 39 subjects as control group. All patients were evaluated by Color Doppler Ultrasound, and/or Spiral Computerised Tomography, Magnetic Resonance Imaging and biopsy. The radiologist performed DPI measurements was blind from the final diagnosis of the other methods.
RESULTS: DPI measurements in the control group ranged from 0.07 to 0.22 (mean value 0.14), in 42 cases with benign lesions (group A) ranged from 0.05 to 0.53 (mean 0.15) and in 34 cases with malignant lesions (group B) ranged from 0.39 to 0.75 (mean 0.53). There was a statistically significant difference in DPI measurements between the control group and group B.
CONCLUSIONS: Our results suggest that the DPI may differentiate malignant from benign focal hepatic lesions and therefore can be used as a screening test in the routine clinical practice.

Entities:  

Mesh:

Year:  2008        PMID: 18294941     DOI: 10.1016/j.dld.2007.12.020

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  2 in total

1.  Effects of Platelet-Derived Endothelial Cell Growth Factor and Doppler Perfusion Index in Patients with Colorectal Hepatic Metastases.

Authors:  Xueming Jiang; Zhixiang Zhang; Na Zhao; Xianghui He; Hao Guo
Journal:  Visc Med       Date:  2016-03-18

2.  Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis.

Authors:  Carmen Fierbinteanu-Braticevici; Ion Dina; Ana Petrisor; Laura Tribus; Lucian Negreanu; Catalin Carstoiu
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.